PI3K/mTOR Inhibitor-2
Based on 1 publication(s) in Google Scholar
PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR. Antitumor activity.
For research use only. We do not sell to patients.
- Purity : 99.10%
- CAS No.: 1848242-58-9
- Formula: C20H13ClF2N4O4S
- Molecular Weight:478.86
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10811
GNE-493PI3K Inhibitor -
HY-15247
VistusertibmTORC Inhibitor -
HY-100470
NSC781406PI3K/mTOR Inhibitor -
HY-13003
Torin 1mTOR Inhibitor -
HY-15772
OsimertinibMutant-Selective EGFR Inhibitor -
HY-15868
HS-173PI3Kα Inhibitor -
HY-10681
GedatolisibPI3K/mTOR Inhibitor -
HY-19962
PaxalisibPI3K/mTOR Inhibitor -
HY-12036
GSK1059615Apoptosis Inducer -
HY-15900
VoxtalisibPI3K Inhibitor -
HY-10681R
Gedatolisib (Standard)PI3K/mTOR Inhibitor -
HY-50910
TemsirolimusmTOR Inhibitor
Publications Citing Use of MedChemExpress (MCE) PI3K/mTOR Inhibitor-2
More
Biological Activity
Description
IC50 & Target
[1]|
PI3Kα 3.4 nM (IC50) |
PI3Kβ 34 nM (IC50) |
PI3Kδ 16 nM (IC50) |
PI3Kγ 1 nM (IC50) |
mTOR 4.7 nM (IC50) |
In Vitro
PI3K/mTOR Inhibitor-2 (Compound 31) inhibits p-AKT and p-p70s6k in MCF-7 cells with IC50s of 11.6 and 89.2 nM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1848242-58-9
-
Appearance Solid
-
Molecular Weight 478.86
-
Formula C20H13ClF2N4O4S
-
Color Light yellow to yellow
-
SMILES
FC1=CC(F)=C(S(=O)(NC2=CC(C(C=C3)=CN4C3=NC=C(Cl)C4=O)=CN=C2OC)=O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
QSAR analysis on a large and diverse set of potent phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using MLR and ANN methods. [Abstract]2022 Apr 12;12(1):6090. PMID: 35414065
Solvent & Solubility
In Vitro:
DMSO : 8.33 mg/mL (17.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0883 mL | 10.4415 mL | 20.8829 mL | 52.2073 mL |
| 5 mM | 0.4177 mL | 2.0883 mL | 4.1766 mL | 10.4415 mL | |
| 10 mM | 0.2088 mL | 1.0441 mL | 2.0883 mL | 5.2207 mL | |
| 15 mM | 0.1392 mL | 0.6961 mL | 1.3922 mL | 3.4805 mL |
PI3K/mTOR Inhibitor-2 Related Classifications
HY-111508 Related Classifications
Powered by Bioz